Annual report pursuant to Section 13 and 15(d)

LICENSE AGREEMENTS - Additional Information - (Detail)

v3.20.2
LICENSE AGREEMENTS - Additional Information - (Detail) - USD ($)
$ in Millions
 2 Months Ended 12 Months Ended
Aug. 31, 2019
Jun. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Qualified Financing Future Cash Payments, Early Payments Obligation   $ 3.4
License agreement    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Proceeds from Issuance of Private Placement, Net of Advisory Fees Payable $ 22.6  
Qualified Financing Future Cash Payments, Early Payments Obligation $ 3.4  
ActiveSite Pharmaceuticals, Inc. [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Maximum Amount of Milestone Events   46.5
First milestone payment due after completion of the preclinical work   $ 1.0
Royalties percentage   2.00%
Minimum | ActiveSite Pharmaceuticals, Inc. [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Milestone Payments   $ 1.0
Maximum | ActiveSite Pharmaceuticals, Inc. [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Milestone Payments   $ 10.0
Xoma | License agreement    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Stock Issued During Period, Shares, Other   162,000
Put Option [Member] | Xoma | License agreement    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Description Of Option Indexed To Issuers Equity Shares   Xoma may exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter